+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Intralesional treatment of cutaneous leishmaniasis with sodium stibogluconate antimony

International Journal of Dermatology 32(8): 610-612
Intralesional treatment of cutaneous leishmaniasis with sodium stibogluconate antimony
Cutaneous leishmaniasis represents a difficult disease to manage in endemic areas. Systemic treatment is hampered by both expense and compliance. Side effects may play a major role in this aspect as well. The effectiveness of intralesional treatment of leishmaniasis was investigated. Seven hundred and ten patients were treated with injections of sodium stibogluconate intralesionally. The clinical diagnosis was confirmed by demonstrating the parasite in the smears obtained from the lesion. Fine insulin needle was used to infiltrate the lesion with sodium stibogluconate (0.5 to 1.0 mL). Generally eight injections were sufficient, but some of the complicated lesions needed up to 24 injections. Sixty-two percent of patients were men. The majority of the study population (64%) were children below 15 years of age. The results showed that 72% of lesions healed completely, 23.9% showed some improvement, while 4.1% showed some deterioration. Lesions of the lips, cheeks, chin, and neck healed faster than lesions in other parts of the body. Side effects were mild and limited to pain at the site of the injection and hyperpigmentation in those who were treated by folk medicine. Intralesional treatment is as effective as the standard systemic antimonials. It offers a less expensive alternative and a low side effects profile. Our findings confirmed the findings of earlier workers. It is recommended for treatment of cutaneous leishmaniasis in endemic areas.

Accession: 002416159

PMID: 8407083

DOI: 10.1111/j.1365-4362.1993.tb05044.x

Download PDF Full Text: Intralesional treatment of cutaneous leishmaniasis with sodium stibogluconate antimony

Related references

Intralesional therapy of cutaneous leishmaniasis with sodium stibogluconate antimony. British Journal of Dermatology 119(1): 53-58, 1988

Intralesional sodium stibogluconate alone or its combination with either intramuscular sodium stibogluconate or oral ketoconazole in the treatment of localized cutaneous leishmaniasis: a comparative study. Journal of the European Academy of Dermatology and Venereology 24(3): 335-340, 2010

Treatment of cutaneous leishmaniasis with intralesional sodium stibogluconate. Journal of the European Academy of Dermatology and Venereology 23(10): 1189-1192, 2009

Cutaneous leishmaniasis: schedules for intralesional treatment with sodium stibogluconate. International Journal of Dermatology 35(8): 594-597, 1996

Cutaneous leishmaniasis from Yemen: treatment with intralesional injection of sodium stibogluconate with local anesthetic. Saudi Medical Journal 18(4): 433-435, 1997

Randomized, double-blind, comparative clinical trial on the efficacy and safety of intralesional sodium stibogluconate and intralesional 7% hypertonic sodium chloride against cutaneous leishmaniasis caused by L. donovani. Journal of Dermatological Treatment 21(5): 286-293, 2010

Efficacy of short-duration (twice weekly) intralesional sodium stibogluconate in treatment of cutaneous Leishmaniasis in India. British Journal of Dermatology 163(4): 854-858, 2011

Randomized, double-blind, controlled, comparative study on intralesional 10% and 15% hypertonic saline versus intralesional sodium stibogluconate in Leishmania donovani cutaneous leishmaniasis. International Journal of Dermatology 54(5): 555-563, 2016

The efficacy of treatment with intralesional meglumine antimoniate alone, compared with that of cryotherapy combined with the meglumine antimoniate or intralesional sodium stibogluconate, in the treatment of cutaneous leishmaniasis. Annals of Tropical Medicine and Parasitology 97(5): 493-498, 2003

Antimony in cutaneous leishmaniasis lesions after sodium stibogluconate administration. Pharmaceutical Research (New York) 11(10 SUPPL ): S373, 1994